The Latest Cardiac and Vascular News
ENGLEWOOD, Colo., Nov. 19, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced it has been ranked 13th in revenue growth among all medical device companies in the U.S. and Canada on Deloitte’s […]
– In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease – Recurrent cardiovascular events in people with type 2 diabetes are […]
VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan […]
The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING RIDGE, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, […]
– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT – – RAPID investigates efficacy of second dose of etripamil for patients with persistent PSVT – – RAPID results expected late 2021/early 2022 – MONTREAL and CHARLOTTE, N.C., Nov. 18, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical […]
– In new results published in The Lancet Diabetes & Endocrinology, Jardiance reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease – Recurrent cardiovascular events in people with […]
Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, Mass., Nov. 17, 2020 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial […]
Third Quarter Revenues Increase 36% to $11.0Million U.S. WatchPATTMRevenues Increase 55% to $8.9Million Full Year 2020 Revenue Guidance of $39.5 Million to $40.5 Million Company to Host Conference Call Today at 8:00am ET, 3:00pm IT CAESAREA, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical […]
Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment DUBLIN, Nov. 16, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England […]
MARLBOROUGH, Mass., Nov. 17, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system. The voluntary recall is related solely to the delivery system, as the valve […]
